Covidien Reports No Procedure Slowdown, Boosts Fiscal 2008 Guidance
This article was originally published in The Gray Sheet
Executive Summary
Covidien's second quarter results, which beat analyst expectations, revealed no sign of a slowdown in U.S. surgical procedure volume, a trend that had been hinted at last month by Johnson & Johnson
You may also be interested in...
J&J Device Sales May Reflect Slowdown In Procedure Volumes, Firm Says
Johnson & Johnson's sluggish growth in first-quarter medical device and diagnostics sales may be due in part to an overall slowdown in surgical procedure volumes in the United States, the company says
Covidien Enters Biologic Tissue Implant Market Via $80 Mil. TSL Acquisition
Covidien gains the Permacol biologic tissue repair implant for hernias and other applications through its $80 million purchase of Tissue Science Laboratories, announced March 12
Covidien Keeps Medical Supplies Unit On Watch List After Sale Of Diaper Biz
Diversified med-tech firm Covidien will continue evaluating potential divestitures following the sale of its diaper-making retail unit, according to the company